335 filings
Page 3 of 17
144
z8b3wxece3ne fyh
9 Feb 24
Notice of proposed sale of securities
4:22pm
SC 13G/A
b09dilwl5jhpvnam
9 Feb 24
Kymera Therapeutics / Atlas Venture Fund X ownership change
4:03pm
SC 13G/A
vkonj
8 Feb 24
Kymera Therapeutics / WELLINGTON MANAGEMENT ownership change
10:21am
SC 13G/A
8p1rets5 rh0
29 Jan 24
Kymera Therapeutics / BlackRock ownership change
3:26pm
4
qzzyrl
23 Jan 24
Kymera Therapeutics / Jeffrey W. Albers ownership change
7:37pm
144
zyu3dg6gueqp5amr03eq
23 Jan 24
Notice of proposed sale of securities
4:19pm
SC 13G/A
b9fwcq3atq0lm guz5
23 Jan 24
Kymera Therapeutics / STATE STREET ownership change
10:31am
SC 13G/A
1qp2d7cpoq6i0
10 Jan 24
Kymera Therapeutics / BAKER BROS. ADVISORS ownership change
4:52pm
4
83o945b6jznhq
9 Jan 24
Kymera Therapeutics / MARK N LAMPERT ownership change
4:49pm
SC 13D/A
1s9 9f1c2y92
9 Jan 24
Kymera Therapeutics / BIOTECHNOLOGY VALUE FUND L P ownership change
4:45pm
4
c3kcs43xhmii3wzvo
5 Jan 24
Kymera Therapeutics / Ellen Chiniara ownership change
5:15pm
8-K
73h8i 5xp
5 Jan 24
Kymera Therapeutics Announces Proposed Public Offering
4:11pm
424B5
sqjzp15ir6n
5 Jan 24
Prospectus supplement for primary offering
4:02pm
424B5
kzbtvnh
4 Jan 24
Prospectus supplement for primary offering
4:06pm
8-K
cmyiw1
4 Jan 24
Regulation FD Disclosure
4:01pm
144
86blq96tp3 egj6rkz7
4 Jan 24
Notice of proposed sale of securities
9:29am
8-K
x4xp8 nv9jxr3
4 Jan 24
STAT6 oral degrader KT-621, with dupilumab-like activity, expected to enter Phase 1 clinical trial in the second half of 2024
7:08am
4
nc6msj1g
2 Jan 24
Kymera Therapeutics / Nello Mainolfi ownership change
5:43pm
4
ee3hij4gtgy j56xv5
6 Nov 23
Kymera Therapeutics / MARK N LAMPERT ownership change
6:07pm
4
53f1zerlyh3ieb
6 Nov 23
Kymera Therapeutics / Nello Mainolfi ownership change
6:00pm